ライフサイエンスコーパス: Mycobacterium bovis

1 and intractable disease of cattle caused by Mycobacterium bovis.

2 h as Leishmania major, Escherichia coli, and Mycobacterium bovis.

3 is operon is specific to M. tuberculosis and Mycobacterium bovis.

4 the most frequently recognized antigens from Mycobacterium bovis.

5 with a strain of M. tuberculosis rather than Mycobacterium bovis.

6 ly differentiate between M. tuberculosis and Mycobacterium bovis.

7 approach and applied it to gene deletions in Mycobacterium bovis.

8 badgers Meles meles naturally infected with Mycobacterium bovis.

9 culosis (TB) is a zoonotic disease caused by Mycobacterium bovis.

10 he principal sigma factor (RpoV) of virulent Mycobacterium bovis, a member of the Mycobacterium tuber

11 Mycobacterium africanum (subtypes I and II), Mycobacterium bovis (along with the attenuated M. bovis

12 bTB, caused by Mycobacterium bovis, also causes disease in the Eurasian

13 ity was observed with some compounds against Mycobacterium bovis and also against hepatitis C virus i

14 ere used to distinguish M. tuberculosis from Mycobacterium bovis and determine phylogenetic lineage.

15 H37Rv isolate and showed 99% identity to the Mycobacterium bovis and M. bovis BCG isolate sequences.

16 It was confirmed to be specific for Mycobacterium bovis and M.caprae cells.

17 ized in the same way that molecular types of Mycobacterium bovis are geographically localized in catt

18 ld badger population naturally infected with Mycobacterium bovis as an example.

19 ability of whole blood to restrict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobact

20 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has va

21 uency and numbers of CD8 T cells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the

22 ial activity against Mycobacterium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vit

23 tion can interact with T cells responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infect

24 lta T cells displayed major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infect

25 cts of an experimental iron-enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infect

26 immunity could be assessed using intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

27 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

28 e and often poor protection conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccin

29 Analysis of Mycobacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which

30 mice that were intracerebrally infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

31 xhibited nanomolar in vitro activity against Mycobacterium bovis bacille Calmette-Guerin and virulent

32 Herein, we demonstrate that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacte

33 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in

34 uperinfecting Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly ho

35 mycobacteria, Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs

36 CCR4 in response to pulmonary infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

37 e were inoculated with an attenuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

38 DNA vaccination combined with Mycobacterium bovis bacillus Calmette Guerin (BCG) repre

39 We screened 3,290 mutant Mycobacterium bovis bacillus Calmette Guerin (BCG) strai

40 the protection afforded by immunization with Mycobacterium bovis bacillus Calmette-Guerin (BCG) admin

41 Candidate vaccines, based upon Mycobacterium bovis bacillus Calmette-Guerin (BCG) all i

42 AS01B, and compared this to vaccination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) alone

43 these questions, cattle were vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) and w

44 was phosphorylated in vivo when expressed in Mycobacterium bovis bacillus Calmette-Guerin (BCG) but n

45 nature of the peripheral cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin (BCG) by co

46 Intravesical administration of Mycobacterium bovis bacillus Calmette-Guerin (BCG) conti

47 Using Mycobacterium bovis bacillus Calmette-Guerin (BCG) cultu

48 Mycobacterium bovis bacillus Calmette-Guerin (BCG) has b

49 rial antigens on the intracellular growth of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in hu

50 Mycobacterium tuberculosis and Mycobacterium bovis bacillus Calmette-Guerin (BCG) induc

51 o track expression of the cytokine following Mycobacterium bovis bacillus Calmette-Guerin (BCG) infec

52 ty-one controls were neither vaccinated with Mycobacterium bovis bacillus Calmette-Guerin (BCG) nor t

53 s of TNF and TNF receptors in the control of Mycobacterium bovis bacillus Calmette-Guerin (BCG) pleur

54 e bone marrow-derived DCs infected with live Mycobacterium bovis Bacillus Calmette-Guerin (BCG) produ

55 Vaccination with Mycobacterium bovis bacillus Calmette-Guerin (BCG) remai

56 on heterologous prime-boost protocols using Mycobacterium bovis bacillus Calmette-Guerin (BCG) to pr

57 n immunodeficiency virus, and the failure of Mycobacterium bovis bacillus Calmette-Guerin (BCG) to pr

58 Mycobacterium bovis Bacillus Calmette-Guerin (BCG) use i

59 d the ability of human antibodies induced by Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

60 Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

61 The Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vacci

62 Moreover, improved Mycobacterium bovis bacillus Calmette-Guerin (BCG) vacci

63 eprae, Mycobacterium tuberculosis (Mtb), and Mycobacterium bovis bacillus Calmette-Guerin (BCG) were

64 eleted from the genome of the vaccine strain Mycobacterium bovis bacillus Calmette-Guerin (BCG), and

65 ients, yet the current tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is c

66 The only vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG), is l

67 rating exudate macrophages to infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG), peak

68 Mycobacterium bovis bacillus Calmette-Guerin (BCG), the

69 g a strain deleted for the KATmt ortholog in Mycobacterium bovis Bacillus Calmette-Guerin (BCG), we s

70 A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette-Guerin (BCG), whic

71 Here, we demonstrate that Mycobacterium bovis bacillus Calmette-Guerin (BCG)-media

72 G and NE in the pulmonary resistance against Mycobacterium bovis bacillus Calmette-Guerin (BCG).

73 r-susceptible to infection by Mycoplasma and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

74 cine for tuberculosis is the live attenuated Mycobacterium bovis bacillus Calmette-Guerin (BCG).

75 4(+) T cells during pulmonary infection with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

76 n Mycobacterium smegmatis (M. smegmatis) and Mycobacterium bovis Bacillus Calmette-Guerin (BCG).

77 omoides polygyrus bakeri on Th1 responses to Mycobacterium bovis bacillus Calmette-Guerin (BCG).

78 (Mphi) isolated from mice given heat-killed Mycobacterium bovis bacillus Calmette-Guerin (HK-BCG) i.

79 In this report, Mycobacterium bovis bacillus Calmette-Guerin and M. tube

80 of either Ass1 or Asl resulted in increased Mycobacterium bovis bacillus Calmette-Guerin and Mycobac

81 the human immune responses to infection with Mycobacterium bovis bacillus Calmette-Guerin and Mycobac

82 f mice made immune by prior vaccination with Mycobacterium bovis bacillus Calmette-Guerin compared wi

83 Comparable infection by Mycobacterium bovis bacillus Calmette-Guerin failed to i

84 MHC-restricted T cells during infection with Mycobacterium bovis bacillus Calmette-Guerin in mice.

85 In contrast, the attenuated Mycobacterium bovis bacillus Calmette-Guerin induces les

86 Following Mycobacterium bovis bacillus Calmette-Guerin infection a

87 unt adaptive immune responses in response to Mycobacterium bovis bacillus Calmette-Guerin infections.

88 tion of M. leprae DNA enhanced nonpathogenic Mycobacterium bovis bacillus Calmette-Guerin intracellul

89 mediated immunity by live attenuated vaccine Mycobacterium bovis bacillus Calmette-Guerin or the adop

90 36-wk-old infants, was incubated with viable Mycobacterium bovis bacillus Calmette-Guerin or TLR liga

91 after aerosol immunization with recombinant Mycobacterium bovis bacillus Calmette-Guerin overexpress

92 ine model that involves immunizing mice with Mycobacterium bovis bacillus Calmette-Guerin to augment

93 genous Ag-specific CD4(+) T cells induced by Mycobacterium bovis bacillus Calmette-Guerin vaccination

94 cient immune control of Helicobacter pylori, Mycobacterium bovis bacillus Calmette-Guerin, and Citrob

95 ion of mice with the intracellular bacterium Mycobacterium bovis bacillus Calmette-Guerin, macrophage

96 cobacterium tuberculosis and by bcg_1279c in Mycobacterium bovis bacillus Calmette-Guerin, plays an i

97 Mycobacterium bovis bacillus Calmette-Guerin, the only v

98 nd trehalose-6,6-dibehenate or infected with Mycobacterium bovis bacillus Calmette-Guerin.

99 ating deletion in the related vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

100 ella enteritidis, Staphylococcus aureus, and Mycobacterium bovis bacillus Calmette-Guerin.

101 erculosis with the attenuated vaccine strain Mycobacterium bovis bacillus Calmette-Guerin.

102 tiate between Mycobacterium tuberculosis and Mycobacterium bovis based on their relative virulence in

103 bit inhibitory ability against the growth of Mycobacterium bovis BCB.

104 ll have to be evaluated against the existing Mycobacterium bovis BCG "gold standard." It is therefore

105 Here, we characterize the glycolipids of Mycobacterium bovis BCG (BCG) that are released into mur

106 We successfully generated recombinant Mycobacterium bovis BCG (rBCG) expressing simian immunod

107 inigenes through combinations of recombinant Mycobacterium bovis BCG (rBCG), electroporated recombina

108 e subcutaneously immunized with DeltafbpA or Mycobacterium bovis BCG and challenged with M. tuberculo

109 ock-in [KI] mice) to determine resistance to Mycobacterium bovis BCG and M. tuberculosis infections a

110 less efficient in restricting the growth of Mycobacterium bovis BCG and M. tuberculosis.

111 m tuberculosis antigens that are absent from Mycobacterium bovis BCG and most environmental mycobacte

112 Mycobacterium bovis BCG and Mycobacterium tuberculosis p

113 Herein we show that M. tuberculosis and Mycobacterium bovis BCG are able to recycle components o

114 on of AFB smears, sputum samples spiked with Mycobacterium bovis BCG at 5 x 10(8) CFU/ml produced 16

115 Introduction of these alleles into Mycobacterium bovis BCG attenuated virulence in macropha

116 The phiRv1 element is not only absent from Mycobacterium bovis BCG but is in different locations wi

117 s infection, mice were immunized with viable Mycobacterium bovis BCG by the aerosol or intravenous ro

118 chanically lyse Bacillus subtilis spores and Mycobacterium bovis BCG cells.

119 negative human sputum spiked with 0 to 10(5) Mycobacterium bovis BCG cells/ml) underwent liquefaction

120 ciency virus (SIVmac) can develop persistent Mycobacterium bovis BCG coinfection and a fatal SIV-rela

121 of simian immunodeficiency virus (SIV(mac))-Mycobacterium bovis BCG coinfection were employed to exp

122 Infection by Mycobacterium bovis BCG does not inhibit IFN-alpha-stimu

123 the mycobacterial antigen 85A (rAd85A), with Mycobacterium bovis BCG followed by rAd85A heterologous

124 rs among ~200 binding regions throughout the Mycobacterium bovis BCG genome, were identified using Ch

125 t of exogenous cAMP on protein expression in Mycobacterium bovis BCG grown under hypoxic versus ambie

126 Importantly, preexisting immunity to Mycobacterium bovis BCG had only a marginal effect on th

127 Moreover, a similar screen in Mycobacterium bovis BCG identified that phthiocerol dimy

128 ly inhibit intracellular bacterial growth of Mycobacterium bovis BCG in macrophages (MPhi) in cocultu

129 sis of bystander cells to restrict growth of Mycobacterium bovis BCG in monocytes.

130 In this study, we examined the growth of Mycobacterium bovis BCG in the lungs under experimental

131 gen-specific Vgamma2Vdelta2(+) T cells after Mycobacterium bovis BCG infection and BCG reinfection, r

132 We examined the role of IL-23 during Mycobacterium bovis BCG infection.

133 Using a Mycobacterium bovis BCG mutant (AS1) lacking a Bacillus

134 letion of the ClpP1P2 level in a conditional Mycobacterium bovis BCG mutant enhanced killing by ADEP

135 We show that an in-frame deletion of Mycobacterium bovis BCG nat results in delayed entry int

136 d iniC (Rv 0341 and Rv 0343) by treatment of Mycobacterium bovis BCG or M. tuberculosis with INH or E

137 mycobacterial strains (Mycobacterium avium, Mycobacterium bovis BCG or Mtb), were exposed to encapsu

138 We found that Mycobacterium bovis BCG or Mycobacterium tuberculosis in

139 put resistance-based phenotypic screen using Mycobacterium bovis BCG over-expressing GuaB2.

140 s of published data for two species; namely, Mycobacterium bovis BCG Pasteur and Mycobacterium smegma

141 n in a PE_PGRS gene (1818(PE_PGRS)) found in Mycobacterium bovis BCG Pasteur, which is the BCG homolo

142 Mycobacterium bovis BCG responded to each stage of hypox

143 ytes stimulated with M. leprae compared with Mycobacterium bovis BCG stimulation.

144 Attenuation of Mycobacterium bovis BCG strain is related to the loss of

145 this study we observe that strain AS-1, the Mycobacterium bovis BCG strain lacking the Rv0522 gene,

146 phages, attenuated M. tuberculosis H37Ra and Mycobacterium bovis BCG strongly induce THP-1 apoptosis,

147 NA (rRNA) and tRNA, from mycobacteria, using Mycobacterium bovis BCG to illustrate the method.

148 culosis promoter-lacZ reporter constructs in Mycobacterium bovis BCG under conditions of ambient air

149 5% carbon dioxide was required for growth of Mycobacterium bovis BCG under microaerophilic (1.3% O(2)

150 tensively in assessing novel vaccines, since Mycobacterium bovis BCG vaccination effectively prolongs

151 Although widely used, Mycobacterium bovis BCG vaccination given at birth does

152 The World Health Organization recommends Mycobacterium bovis BCG vaccination in areas of high tub

153 The effect of Mycobacterium bovis BCG vaccination on interleukin-1 bet

154 her primary nor memory immunity conferred by Mycobacterium bovis BCG vaccination was affected in mice

155 To determine whether Mycobacterium bovis BCG vaccination would alter gamma in

156 is, which was comparable to that provided by Mycobacterium bovis BCG vaccination.

157 ctive capacity as a potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea

158 Mycobacterium bovis BCG vaccine provides only partial pr

159 Three commonly used Mycobacterium bovis BCG vaccine strains elicited differe

160 Beijing lineage strains) may be resistant to Mycobacterium bovis BCG vaccine-induced antituberculosis

161 enerate protection equivalent to that of the Mycobacterium bovis BCG vaccine.

162 been vaccinated with the partially effective Mycobacterium bovis BCG vaccine.

163 ections and do so better than the suboptimal Mycobacterium bovis BCG vaccine.

164 Mycobacterium bovis BCG was cultivated at high and low g

165 The phosphatase activity in whole cells of Mycobacterium bovis BCG was significantly less than that

166 isolated PAS-resistant transposon mutants of Mycobacterium bovis BCG with insertions in the thymidyla

167 prepared and evaluated for activity against Mycobacterium bovis BCG with the thiourea-containing iso

168 tions, the highly related but non-pathogenic Mycobacterium bovis BCG yields partially ( approximately

169 The only available vaccine (Mycobacterium bovis BCG) protects children from dissemin

170 Previously, we found that Mycobacterium bovis BCG, a human tuberculosis vaccine, s

171 ficient lysis of Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium marinum.

172 atory strains of Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium smegmatis.

173 an macrophages could survive infection, kill Mycobacterium bovis BCG, and severely limit the replicat

174 be propagated in Mycobacterium smegmatis and Mycobacterium bovis BCG, and their compatibility with ot

175 dimycocerosyl phthiocerol, were cloned from Mycobacterium bovis BCG, and their promoters were analyz

176 d lung tissue in a mouse model infected with Mycobacterium bovis BCG, as tested by real-time polymera

177 from virulent M. tuberculosis and attenuated Mycobacterium bovis BCG, bacteria were grown in broth cu

178 The CRP(Mt) ortholog in Mycobacterium bovis BCG, CRP(BCG), is dysfunctional in a

179 A mutant strain of Mycobacterium bovis BCG, defective in the transport of s

180 M.tb infection or whether vaccination with, Mycobacterium bovis BCG, has a similar effect.

181 accine against tuberculosis, live attenuated Mycobacterium bovis BCG, has variable efficacy, but deve

182 ine cocktail or with the current TB vaccine, Mycobacterium bovis BCG, induced considerable antituberc

183 gues exhibited balanced profiles of potency (Mycobacterium bovis BCG, M tuberculosis H37Rv), selectiv

184 g to the Corynebacterineae suborder, namely, Mycobacterium bovis BCG, Mycobacterium smegmatis, and Co

185 Screening for amino acid auxotrophs of Mycobacterium bovis BCG, obtained by transposon mutagene

186 , metabolome profiling in the Mtb surrogate, Mycobacterium bovis BCG, reveals significant changes in

187 st everyone is vaccinated early in life with Mycobacterium bovis BCG, the currently available vaccine

188 4(+) T cells to suppress T cell responses to Mycobacterium bovis BCG, the live vaccine that provides

189 We have discovered that Mycobacterium bovis BCG, the tuberculosis vaccine strain

190 In the lungs of mice vaccinated with Mycobacterium bovis BCG, there was an accumulation of CD

191 of the BCG2529 gene, the Rv2509 homologue in Mycobacterium bovis BCG, was unable to grow following th

192 ied a new cAMP-associated regulon in Mtb and Mycobacterium bovis BCG, which is distinct from the prev

193 ing and intravital multiphoton microscopy of Mycobacterium bovis BCG-induced liver granulomas.

194 tudy we analyzed humoral immune responses in Mycobacterium bovis BCG-vaccinated and control cattle (i

195 le of splenocytes restimulated in vitro from Mycobacterium bovis BCG-vaccinated and naive animals.

196 macrophages harvested from nonvaccinated and Mycobacterium bovis BCG-vaccinated guinea pigs were infe

197 Mycobacterium bovis BCG-vaccinated guinea pigs were inje

198 immune T cells and macrophages obtained from Mycobacterium bovis BCG-vaccinated guinea pigs.

199 sentially equivalent to the survival time of Mycobacterium bovis BCG-vaccinated mice (294 +/- 15 days

200 ne activities in Mycobacterium smegmatis and Mycobacterium bovis BCG.

201 BALB/c mice were infected by aerosol with Mycobacterium bovis BCG.

202 riven by the heat shock promoter, phsp60, of Mycobacterium bovis BCG.

203 wth of extended-stationary-phase cultures of Mycobacterium bovis BCG.

204 icantly enhanced upon prior vaccination with Mycobacterium bovis BCG.

205 sA2, and desA3, were cloned and expressed in Mycobacterium bovis BCG.

206 e individuals or individuals vaccinated with Mycobacterium bovis BCG.

207 ene) by using a promoter-GFP fusion assay in Mycobacterium bovis BCG.

208 d protection equivalent to that conferred by Mycobacterium bovis BCG.

209 ility of intracellular but not extracellular Mycobacterium bovis BCG.

210 cterium tuberculosis and its close relative, Mycobacterium bovis (BCG) contain five genes whose predi

211 and is not functional in the closely related Mycobacterium bovis because of an inactivating frameshif

212 analyses were used to assess transmission of Mycobacterium bovis between humans.

213 The risk of Mycobacterium bovis bloodstream infection (BSI) in bacil

214 icans hyphae and extracellular aggregates of Mycobacterium bovis, but not in response to small yeast

215 to explore opportunities for transmission of Mycobacterium bovis [causal agent of bovine tuberculosis

216 Mycobacterium bovis causes tuberculosis in a wide variet

217 omagnetic separation (IMS) method to isolate Mycobacterium bovis cells from lymph node tissues.

218 f BCG against Mycobacterium tuberculosis and Mycobacterium bovis challenge in animal models, for effi

219 Bovine tuberculosis (bTB), caused by Mycobacterium bovis, continues to be a serious economic

220 , mycobacterial crude cell wall extract, and Mycobacterium bovis culture filtrate proteins.

221 test is compromised by vaccination with the Mycobacterium bovis-derived vaccine strain bacille Calme

222 nd tissues of cattle naturally infected with Mycobacterium bovis Detailed postmortem and immunohistoc

223 , and their assessment as typing tools in 47 Mycobacterium bovis field isolates and nine MTBC strains

224 nt apoptosis as a result of infection with a Mycobacterium bovis field strain.

225 notyping techniques that have differentiated Mycobacterium bovis from Mycobacterium tuberculosis sinc

226 erculosis (bTB), a zoonosis mainly caused by Mycobacterium bovis has severe socio-economic consequenc

227 mental models of protective immunity against Mycobacterium bovis: (i) vaccination with M. bovis BCG a

228 t overlap geographically with the strains of Mycobacterium bovis in Great Britain.

229 orescence for rapid, definitive detection of Mycobacterium bovis in lymph node specimens from 38 catt

230 WC1(+) gammadelta T cells of Mycobacterium bovis-infected cattle are highly responsiv

231 Accurately identifying Mycobacterium bovis-infected cattle is critical for bovi

232 s adenylate cyclase (CyaA) are recognized by Mycobacterium bovis-infected cattle more effectively tha

233 Moreover, Mycobacterium bovis-infected IRAK-4-knockout macrophages

234 A TB incident was detection of new Mycobacterium bovis infection (post-mortem confirmed) in

235 ngly recognized by cattle with early primary Mycobacterium bovis infection and by healthy MTB-sensiti

236 ods capable of detecting and differentiating Mycobacterium bovis infection from other pathogenic and

237 Mycobacterium bovis infection has been described in many

238 ategy in countries where there is persistent Mycobacterium bovis infection in wildlife and in develop

239 Promoting effective immunity to Mycobacterium bovis infection is a challenge that is of

240 Current assays used to detect Mycobacterium bovis infection lack accuracy, especially

241 Mycobacterium bovis infection of cattle represents a nat

242 dentify peptides that are immunogenic during Mycobacterium bovis infection of cattle.

243 Disease due to human Mycobacterium bovis infection usually occurs in older pa

244 To estimate mortality for Mycobacterium bovis infections and morbidity and mortali

245 he surface of Mycobacterium tuberculosis and Mycobacterium bovis, initiates responses that can lead b

246 Tuberculosis (TB) caused by Mycobacterium bovis is a re-emerging disease of livestoc

247 Bovine tuberculosis caused by Mycobacterium bovis is a serious and economically import

248 Mycobacterium bovis is best identified by screening thos

249 Mycobacterium bovis is naturally resistant to the antitu

250 Mycobacterium bovis is responsible for bovine tuberculos

251 Mycobacterium bovis is the causative agent of bovine tub

252 The bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis is used in many parts of the world a

253 Bovine tuberculosis (bTB; Mycobacterium bovis) is a bacterial infection of cattle

254 Calmette-Guerin (BCG), an attenuated form of Mycobacterium bovis, is associated with persistent activ

255 lmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, is widely used as adjunctive therap

256 Here, Whole-Genome Sequencing of Mycobacterium bovis isolated from tissues with TB-like l

257 Mycobacterium bovis isolates carry restricted allelic va

258 dy set of 180 Mycobacterium tuberculosis and Mycobacterium bovis isolates having low copy numbers of

259 the fundamental in vitro characteristics of Mycobacterium bovis--its requirement for pyruvate in gly

260 The attenuated strain of Mycobacterium bovis known as bacille Calmette-Guerin (BC

261 a coli ( E. coli) and for analysis of MAs in Mycobacterium bovis ( M. bovis) and M. tuberculosis lipi

262 eolar macrophage (bAM) transcriptome, due to Mycobacterium bovis (M. bovis) infection, has been well

263 duced greater IL-22 and IL-17A production in Mycobacterium bovis (M. bovis)-infected cattle compared

264 Although the bovine tuberculosis (TB) agent, Mycobacterium bovis, may infect humans and cause disease

265 etween 72 and 96 h), in cattle infected with Mycobacterium bovis (n = 22) and animals sensitized by e

266 s to determine the minimum infective dose of Mycobacterium bovis necessary to stimulate specific immu

267 The agent of bTB, Mycobacterium bovis, persists in cattle populations worl

268 Mycobacterium bovis produced only low levels of nitrite,

269 ma formation in response to bead-immobilized Mycobacterium bovis-purified protein derivative in aged

270 e to reproducibly generate cavities by using Mycobacterium bovis Ravenel, M. bovis AF2122, M. bovis B

271 .C.13, H37Rv, and H37Ra) and two isolates of Mycobacterium bovis (Ravenel and BCG) to reactive oxygen

272 Bovine tuberculosis (BTB) caused by Mycobacterium bovis remains a major problem in both the

273 The data reveal that Mycobacterium bovis RNAP exhibits an unstable RPo that i

274 ty, and both the incidence and prevalence of Mycobacterium bovis show marked variation in space.

275 advantages, we investigated the potential of Mycobacterium bovis-specific antigens to stimulate delay

276 ular composition and bacterial protection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)

277 both acute and chronic granulomas induced by Mycobacterium bovis strain bacillus Calmette-Guerin (BCG

278 4 as a selective agent, transposon-generated Mycobacterium bovis strain BCG (M. bovis) mutants that c

279 We applied this to cultured Mycobacterium bovis strain BCG DNA and to combined cultu

280 ct 10 colony-forming units of the attenuated Mycobacterium bovis strain BCG in human sputum in the pr

281 cterium tuberculosis strain Beijing 1471 and Mycobacterium bovis strains B2 and MP287/03) or the H37R

282 city of rough morphology M. tuberculosis and Mycobacterium bovis strains was greater than smooth "M.

283 creasingly recognized MtbC groupings include Mycobacterium bovis subsp. caprae and "Mycobacterium tub

284 ette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that is used widely as a vaccine for

285 rculosis vaccine, is an attenuated mutant of Mycobacterium bovis that was isolated after serial subcu

286 ell-characterised population with an endemic Mycobacterium bovis (the causative agent of bovine/zoono

287 Mycobacterium bovis, the aetiological agent of bovine tu

288 (Meles meles) are implicated in transmitting Mycobacterium bovis, the causative agent of bovine tuber

289 a series of attempts to limit the spread of Mycobacterium bovis, the causative agent of bovine tuber

290 The incidence of Mycobacterium bovis, the causative agent of bovine tuber

291 The incidence of Mycobacterium bovis, the causative agent of bovine tuber

292 etic relatedness, and elevated prevalence of Mycobacterium bovis, the causative agent of TB.

293 Mycobacterium tuberculosis and Mycobacterium bovis, the causative agents of human and b

294 tantial evidence suggests that the burden of Mycobacterium bovis, the cause of bovine tuberculosis, m

295 ry, one secondary case due to drug-resistant Mycobacterium bovis was found.

296 vage pathway of the bovine tubercle bacillus Mycobacterium bovis was reported defective due to a muta

297 us, 1758) population naturally infected with Mycobacterium bovis, we built an integrated population m

298 fected with either M. avium subsp. avium and Mycobacterium bovis were exposed to the array to identif

299 of bacille Calmette-Guerin but not wild-type Mycobacterium bovis, which both lack a functional nicoti

300 ore than 50 million cattle are infected with Mycobacterium bovis worldwide, resulting in severe econo